European Medical Agency Clears Amyloidosis Drug

A big step forward for those with amyloidosis!

The European Medicines Agency (EMA) granted Pfizer a positive recommendation for the approval of its treatment for amyloidosis, a rare disorder that occurs in patients with cardiomyopathy.

What is Amyloidosis?

Amyloidosis occurs when abnormal proteins called amyloids build up and form deposits. The deposits can collect in organs such as the kidney and heart. This can cause the organs to become stiff and unable to work the way they should. There are six main types of amyloidosis:

  • Primary (AL) – with no known cause
  • Secondary (AA) – caused by another disease, including some types of cancer
  • Familial (ATTR & non-ATTR) – passed down through genes
  • Dialysis-related (DRA)
  • Senile systemic (SSA or Wild-Type)
  • Organ-specific

Symptoms can vary, depending upon which organs are affected. Treatment depends on the type of amyloidosis you have. The goal is to help with symptoms and limit the production of proteins. If another disease is the cause, it needs to be treated.

To read more about amyloidosis, click here.

First of its Kind

Pfizer’s drug in question, Vyndaqel, would be the first approved treatment for amyloidosis in the European Union and it couldn’t come fast enough: many patients only live 2-3 years following diagnosis.

We’ve previously covered Vyndaqel earlier this year when it passed a major milestone in the FDA here in the USA.

What Happens Now?

The EMA’s recommendation will now be reviewed by the European Commission and a final decision is expected in the coming months.

 


Are you part of the amyloidosis community ? Share your stories, thoughts, and hopes with the Patient Worthy community!

Share this post

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email
Close Menu